trending Market Intelligence /marketintelligence/en/news-insights/trending/6La1g_Z-cntD5J5eveR_Pg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

NeoGenomics prices $148.8M common stock offering

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


NeoGenomics prices $148.8M common stock offering

NeoGenomics Inc. priced an offering of 7 million common stock at $21.25 each.

The Fort Myers, Fla.-based company also granted underwriters a 30-day option to buy up to an additional 1,050,000 common shares at the same price.

The company, which focuses on cancer genetics testing, expects gross proceeds of $148.8 million from the offering. Net proceeds will be used for general corporate purposes.

NeoGenomics may also use the proceeds from the offer to acquire or invest in complementary business and technologies.

Morgan Stanley, SVB Leerink and William Blair acted as representatives of the underwriters and book-running managers for the offering, while Cantor, Craig-Hallum Capital Group, Needham & Co., Raymond James and Stephens Inc. acted as co-managers.